Authors:
Dumez, H
Guetens, G
De Boeck, G
Highley, M
Tjaden, UR
Maes, R
Hanauske, A
Van Oosterom, AT
de Bruijn, EA
Citation: H. Dumez et al., Quantitation of suspensions (MESED). Application of MESED-GC/MS in the quantitation of ifosfamide mustard in erythrocytes, plasma, and plasma water, J SEP SCI, 24(2), 2001, pp. 123-128
Authors:
Boddy, AV
Griffin, MJ
Sludden, J
Thomas, HD
Fishwick, K
Wright, JG
Plummer, ER
Highley, M
Calvert, AH
Citation: Av. Boddy et al., Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer, CANC CHEMOT, 48(1), 2001, pp. 15-21
Authors:
Dumez, H
Highley, M
Guetens, G
De Boeck, G
Hanauske, A
van Oosterom, AT
Maes, RAA
de Bruijn, EA
Harper, P
Citation: H. Dumez et al., Erythrocytes and the transfer of anticancer drugs and metabolites: A possible relationship with therapeutic outcome, SEMIN ONCOL, 28(2), 2001, pp. 24-28
Authors:
Zhang, ZD
Guetens, G
De Boeck, G
Van Cauwenberghe, K
Maes, RAA
Ardiet, C
van Oosterom, AT
Highley, M
de Bruijn, EA
Tjaden, UR
Citation: Zd. Zhang et al., Simultaneous determination of the peptide-mitomycin KW-2149 and its metabolites in plasma by high-performance liquid chromatography, J CHROMAT B, 739(2), 2000, pp. 281-289
Authors:
Schrijvers, D
Pronk, L
Highley, M
Bruno, R
Locci-Tonelli, D
De Bruijn, E
Van Oosterom, AT
Verweij, J
Citation: D. Schrijvers et al., Pharmacokinetics of ifosfamide are changed by combination with docetaxel -Results of a phase I pharmacologic study, AM J CL ONC, 23(4), 2000, pp. 358-363
Authors:
Schrijvers, D
Catimel, G
Highley, M
Hoppener, FJP
Dirix, L
De Bruijn, E
Droz, JP
Van Oosterom, AT
Citation: D. Schrijvers et al., KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study, ANTI-CANC D, 10(7), 1999, pp. 633-639
Authors:
Calvert, AH
Ghokul, S
Al-Azraqi, A
Wright, J
Lind, M
Bailey, N
Highley, M
Siddiqui, N
Lunec, J
Sinha, D
Boddy, A
Roberts, F
Fenwick, J
Citation: Ah. Calvert et al., Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene, SEMIN ONCOL, 26(1), 1999, pp. 90-94